Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0L9HX
|
|||
| Former ID |
DCL001037
|
|||
| Drug Name |
Voclosporin
|
|||
| Synonyms |
Luveniq; ISAtx-247; ISA-247; UNII-2PN063X6B1; ISATX247; 515814-01-4; ISA247; 2PN063X6B1; ISA 247; trans-ISA-247; LX211; Voclosporin (USAN/INN); Voclosporin [USAN:INN]; Voclera; 3odi; LX-211; LX-214; ISA247, Luveniq; AC1OCFHS; R-1524; SCHEMBL12632344; CHEBI:135957; (E)-ISA-247; DB11693; 515814-00-3; HY-106638; CS-0026210; D09033; Cyclosporin A, 6-((2S,3R,4R)-3-hydroxy-4-methyl-2-(methylamino)-6,8-nonadienoic acid)-; 368455-04-3; Luveniq; Voclosporin [USAN]; R 1524; Trans-ISA 247; Trans-ISA-247; TrkA-IgG
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Lupus nephritis [ICD-11: 4A40.0Y] | Approved | [1] | |
| Psoriasis vulgaris [ICD-11: EA90; ICD-9: 696] | Phase 3 | [2] | ||
| Kidney disease [ICD-11: GC2Z; ICD-10: T86; ICD-9: 996] | Phase 2 | [2] | ||
| Company |
Isotechnika
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C63H111N11O12
|
|||
| Canonical SMILES |
CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC=C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C
|
|||
| InChI |
1S/C63H111N11O12/c1-25-27-28-29-41(15)53(76)52-57(80)66-44(26-2)59(82)68(18)34-49(75)69(19)45(30-35(3)4)56(79)67-50(39(11)12)62(85)70(20)46(31-36(5)6)55(78)64-42(16)54(77)65-43(17)58(81)71(21)47(32-37(7)8)60(83)72(22)48(33-38(9)10)61(84)73(23)51(40(13)14)63(86)74(52)24/h25,27-28,35-48,50-53,76H,1,26,29-34H2,2-24H3,(H,64,78)(H,65,77)(H,66,80)(H,67,79)/b28-27+/t41-,42+,43-,44+,45+,46+,47+,48+,50+,51+,52+,53-/m1/s1
|
|||
| InChIKey |
BICRTLVBTLFLRD-PTWUADNWSA-N
|
|||
| CAS Number |
CAS 515814-00-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| ChEBI ID |
CHEBI:135957
|
|||
| SuperDrug ATC ID |
L04AD03
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021 | |||
| REF 2 | Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.